Trial Profile
A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Registrational
- Acronyms HALO; HALO LTS
- Sponsors Teva Branded Pharmaceutical Products R&D
- 06 Dec 2023 According to a Teva Pharmaceuticals media release, data from this study were presented at the 2023 European Headache Congress.
- 06 Dec 2023 Post hoc results presented in a Teva Pharmaceuticals media release.
- 08 Sep 2022 According to a Teva Pharmaceuticals media release, Results of pooled data from two previous six-month studies: HALO and FOCUS presented at the Migraine Trust International Symposium (MTIS)